logo
Plus   Neg
Share
Email

Sanofi:FDA Reviews DUPIXENT As Potential Treatment For Moderate-to-Severe Asthma

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application
or sBLA of DUPIXENT or dupilumab as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-severe asthma. Per the Prescription Drug User Fee Act, the target action date is October 20, 2018.

DUPIXENT is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signaling proteins (cytokines) that contribute to Type 2 inflammation in moderate-to-severe asthma.

The application is supported by clinical data from 2,888 adults and adolescents who participated in three pivotal trials from the LIBERTY ASTHMA clinical development program. Detailed results from the Phase 3 QUEST and VENTURE trials will be submitted for presentation at medical meetings later this year.

The potential use of DUPIXENT in asthma is currently under clinical development and the safety and efficacy for this use have not been fully evaluated by any regulatory authority.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A $716 billion defense policy bill easily cleared the Senate on Monday, although the legislation must still be reconciled with the version previously approved by the House. The Senate voted 85 to 10 in favor of the National Defense Authorization Act, which authorizes U.S. military spending for fiscal 2019. Voip-Pal.com Inc. has filed a lawsuit against Amazon Inc., accusing Alexa's calling and messaging services of infringing its patents. The lawsuit, filed by Voip-Pal in the U.S. District Court in Nevada, accuses Amazon's Alexa calling and messaging system of using Voip-Pal's patented technologies to direct voice/video calls and voice messages to both Amazon subscribers and non-subscribers. Canada is a step closer to becoming the first G-7 nation to legalize marijuana nationwide after the House of Commons voted to allow recreational use. The bill will now go back to the country's Senate, which had already approved a version of the bill. On Monday, the House of Commons voted 205 to 82 in favor of the Bill C-45, known as the Cannabis Act.
Follow RTT